TMS Co

TMS Co EBITDA per Employee

The EBITDA per Employee of TMS Co (4891.T) as of Nov 4, 2026 is -59.74 M JPY. In the previous year, EBITDA per Employee was -64.84 M JPY — a change of -7.87% (higher).

EBITDA per Employee

-59.74 MJPY

YoY

-7.87%

Last updated:

EBITDA per Employee of TMS Co is 2026 -59.74 M JPY. EBITDA per Employee of TMS Co was 2025 -64.84 M JPY. It decreases by -7.87% higher compared to the previous year.

The TMS Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2021
-51.23 M JPY
Jan 1, 2022
81.13 M JPY
Jan 1, 2023
-36.79 M JPY
Jan 1, 2024
-66.99 M JPY
Jan 1, 2025
-64.84 M JPY
Jan 1, 2026
-59.74 M JPY
The TMS Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-59.74 MJPY-7.87%
-64.84 MJPY-3.21%
-66.99 MJPY+82.10%
-36.79 MJPY-145.34%
81.13 MJPY-258.39%
-51.23 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

EBITDA per Employee of TMS Co is -59.74 M JPY in 2026.

EBITDA per Employee of TMS Co changed from -64.84 M JPY to -59.74 M JPY, representing a -7.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee TMS Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TMS Co

All Key Metrics — TMS Co